| Type: | mab |
| Mab Type: | BiTE |
| Target: | BCMA-expressing multiple myeloma cells and CD3-expressing T-cells |
| Tradename: | Elrexfio |
| Dailymedid: | Elranatamab |
| Pregnancy Au: | C |
| Routes Of Administration: | Subcutaneous |
| Atc Prefix: | None |
| Legal Au: | S4 |
| Legal Au Comment: | [1] [2] [3] |
| Legal Ca: | Rx-only |
| Legal Ca Comment: | /Schedule D[4] [5] [6] [7] |
| Legal Us: | Rx-only |
| Legal Us Comment: | [8] [9] |
| Legal Eu: | Rx-only |
| Legal Eu Comment: | [10] |
| Cas Number: | 2408850-14-4 |
| Drugbank: | DB15395 |
| Unii: | L0HR9A577V |
| Kegg: | D12058 |
| Synonyms: | elranatamab-bcmm |
| C: | 6440 |
| H: | 9958 |
| N: | 1738 |
| O: | 2010 |
| S: | 49 |
Elranatamab, sold under the brand name Elrexfio, is a medication used for the treatment of multiple myeloma. Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.[11] [12] Elranatamab is given by subcutaneous injection.
The most common side effects include cytokine release syndrome, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia (fever).
Elranatamab was approved for medical use in the United States in August 2023,[13] [14] in the European Union in December 2023, and in Canada in December 2023.
Elranatamab is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.[15]
The most common adverse reactions include cytokine release syndrome, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia.
The US Food and Drug Administration (FDA) prescribing information for elranatamab has a boxed warning for life-threatening or fatal cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity.
The safety and effectiveness of elranatamab was evaluated in MagnetisMM-3 (NCT04649359), an open-label, single-arm, multi-center study that included participants with relapsed/refractory multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody. Overall, the study consisted of 97 participants naïve to prior BCMA-directed therapy and who had previously received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
The FDA granted the application for elranatamab priority review, breakthrough therapy, and orphan drug designations; and granted approval of Elrexfio to Pfizer Inc.
In October 2023, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Elrexfio, intended for the treatment of multiple myeloma. The applicant for this medicinal product is Pfizer Europe MA EEIG.[16]
In 2023, elranatamab was approved for medical use in the United States, in the European Union, and in Canada.
Elranatamab is the international nonproprietary name.[17]
Elranatamab is sold under the brand name Elrexfio.